Drug Profile
Research programme: histone deacetylase-6 protein inhibitors - Karus Therapeutics
Alternative Names: HDAC-6 inhibitors - Karus; HDAC6i - Karus; KAR 2581; KAR 3000; KAR 3166Latest Information Update: 29 Mar 2023
Price :
$50
*
At a glance
- Originator Karus Therapeutics
- Developer Karus Therapeutics; Kings College London; Queen Elizabeth Hospital
- Class Antineoplastics; Depsipeptides; Small molecules
- Mechanism of Action HDAC6 protein inhibitors; Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haematological malignancies; Inflammation; Psoriasis; Rheumatoid arthritis; Solid tumours; Transplant rejection
Most Recent Events
- 31 Mar 2021 Discontinued - Preclinical for Haematological malignancies in United Kingdom (PO)
- 31 Mar 2021 Discontinued - Preclinical for Solid tumours in United Kingdom (PO)
- 31 Mar 2021 Discontinued - Preclinical for Transplant rejection in United Kingdom (PO)